The additional burden of HCV infection in HIV–HCV-coinfected individuals may have some consequences on adherence to HAART. Few studies have explored the pattern of correlates of non-adherence to HAART while simultaneously considering the impact of HCV treatment and depressive symptoms on adherence to HAART. We used longitudinal data to assess factors associated with non-adherence to HAART.
Methods
The French national prospective cohort ANRS-CO13-HEPAVIH is a multicentrer cohort, which recruited 1,175 HIV–HCV-coinfected patients in 17 hospital outpatient units delivering HIV and HCV care in France between October 2006 and June 2008. For this analysis, we selected participants on HAART with self-reported data for adherence to HAART (n=727 patients, 1,190 visits). Data were collected using self-administered questionnaires and medical records. A mixed logistic regression model based on an exchangeable correlation matrix was used to identify factors associated with non-adherence to HAART.
Results
Patients reported non-adherence to HAART in 808 (68%) of the 1,190 visits. Four variables remained associated with non-adherence to HAART after multivariate analysis: hazardous alcohol consumption, cocaine use and depressive symptoms, regardless of whether treatment for depression was being received. Finally, patients being treated for HCV infection were less likely to be non-adherent to HAART.
Conclusions
Besides the problem of polydrug use, two other dimensions deserve special attention when considering adherence to HAART in HIV–HCV-coinfected patients. Access to HCV treatment should be encouraged as well adequate treatment for depression in this population to improve adherence and response to HAART.
References
1.
OrtegoC., Huedo-MedinaT.B., LlorcaJ.Adherence to highly active antiretroviral therapy (HAART): a meta-analysis. AIDS Behav2011; 15: 1381–1396.
2.
MillsE.J., NachegaJ.B., BangsbergD.R.Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med2006; 3: e438.
3.
LalL.S., GrimesR.M., SwintJ.M., RisserJ.A retrospective study to determine the impact of medical- and lifestyle-based contraindications to a prescribed HAART regimen on clinical outcomes and adherence. J Clin Pharm Ther2006; 31: 429–439.
4.
LeaverC.A., BarghG., DunnJ.R., HwangS.W.The effects of housing status on health-related outcomes in people living with HIV: a systematic review of the literature. AIDS Behav2007; 11 Suppl: 85–100.
5.
PalepuA., TyndallM.W., ChanK., WoodE., MontanerJ.S., HoggR.S.Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes. Antivir Ther2004; 9: 713–719.
6.
FrickP., TapiaK., GrantP., NovotnyM., KerzeeJ.The effect of a multidisciplinary program on HAART adherence. AIDS Patient Care STDS2006; 20: 511–524.
7.
WellsK.B., GoldingJ.M., BurnamM.A.Psychiatric disorder in a sample of the general population with and without chronic medical conditions. Am J Psychiatry1988; 145: 976–981.
8.
OrlandoM., BurnamM.A., BeckmanR.Re-estimating the prevalence of psychiatric disorders in a nationally representative sample of persons receiving care for HIV: results from the HIV Cost and Services Utilization Study. Int J Methods Psychiatr Res2002; 11: 75–82.
9.
StaraceF., AmmassariA., TrottaM.P.Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr2002; 31Suppl 3: S136–S139.
10.
TreismanG., AngelinoA.Interrelation between psychiatric disorders and the prevention and treatment of HIV infection. Clin Infect Dis2007; 45Suppl 4: S313–S317.
11.
MarkowitzJ.C., KocsisJ.H., FishmanB.Treatment of depressive symptoms in human immunodeficiency virus-positive patients. Arch Gen Psychiatry1998; 55: 452–457.
12.
BraitsteinP., JusticeA., BangsbergD.R.Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort. AIDS2006; 20: 323–331.
13.
YoonJ.C., CraneP.K., CiechanowskiP.S., HarringtonR.D., KitahataM.M., CraneH.M.Somatic symptoms and the association between hepatitis C infection and depression in HIV-infected patients. AIDS Care2011; 23: 1208–1218.
14.
CartaM.G., AngstJ., MoroM.F.Association of chronic hepatitis C with recurrent brief depression. J Affect Disord2012; 141: 361–366.
15.
SchlaakJ.F., TripplerM., Hoyo-BecerraC.Selective hyper-responsiveness of the interferon system in major depressive disorders and depression induced by interferon therapy. PLoS ONE2012; 7: e38668.
16.
DoreG.Access to HCV treatment for people with HIV/ HCV.14th International AIDS Conference. 22–27 July 2012, Washington, DC, USA. Abstract THSS0202.
17.
LokoM.A., SalmonD., CarrieriP.The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006–2010. BMC Infect Dis2010; 10: 303.
18.
McLellanA.T., KushnerH., MetzgerD.The fifth edition of the addiction severity index. J Subst Abuse Treat1992; 9: 199–213.
19.
BradleyK.A., DeBenedettiA.F., VolkR.J., WilliamsE.C., FrankD., KivlahanD.R.AUDIT-C as a brief screen for alcohol misuse in primary care. Alcohol Clin Exp Res2007; 31: 1208–1217.
20.
JusticeA.C., HolmesW., GiffordA.L.Development and validation of a self-completed HIV symptom index. J Clin Epidemiol2001; 54Suppl 1: S77–S90.
21.
FurherR., RouillonF.[La version française de l'échelle CES-D. Description and translation of the auto-evaluation.]Psychiatr Psychobiol1989; 4: 163–166. French.
22.
RadloffL.The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas1977; 1: 385–401.
23.
DuranS., SolasC., SpireB.'Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy?’ A comparison between patients’ self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study. AIDS2001; 15: 1075–1077.
24.
SorianoV., ShermanK.E., RockstrohJ.Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients. AIDS2011; 25: 2197–2208.
25.
StraderD.B.Coinfection with HIV and hepatitis C virus in injection drug users and minority populations. Clin Infect Dis2005; 41Suppl 1: S7–S13.
26.
SteinM.D., HermanD.S., SolomonD.A.Adherence to treatment of depression in active injection drug users: the Minerva Study. J Subst Abuse Treat2004; 26: 87–93.
27.
SchaeferM., CapuronL., FriebeA.Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol2012; 57: 1379–1390.
28.
LibmanH., SaitzR., NunesD.Hepatitis C infection is associated with depressive symptoms in HIV-infected adults with alcohol problems. Am J Gastroenterol2006; 101: 1804–1810.
29.
GonzalezJ.S., BatchelderA.W., PsarosC., SafrenS.A.Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. J Acquir Immune Defic Syndr2011; 58: 181–187.
MichelL., VillesV., DabisF.Role of treatment for depressive symptoms in relieving the impact of fatigue in HIV-HCV co-infected patients: ANRS CO13 HEPAVIH, France, 2006–2008. J Viral Hepat2010; 17: 650–660.
32.
KresinaT.F., FlexnerC.W., SinclairJ.Alcohol use and HIV pharmacotherapy. AIDS Res Hum Retroviruses2002; 18: 757–770.
33.
SametJ.H., HortonN.J., MeliS., FreedbergK.A., PalepuA.Alcohol consumption and antiretroviral adherence among HIV-infected persons with alcohol problems. Alcohol Clin Exp Res2004; 28: 572–577.
34.
CampbellJ.V., HaganH., LatkaM.H.High prevalence of alcohol use among hepatitis C virus antibody positive injection drug users in three US cities. Drug Alcohol Depend2006; 81: 259–265.
35.
LeggioL., FerrulliA., ZambonA.Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection. Addict Behav2012; 37: 561–564.
36.
DrumrightL.N., HaganH., ThomasD.L.Predictors and effects of alcohol use on liver function among young HCV-infected injection drug users in a behavioral intervention. J Hepatol2011; 55: 45–52.
37.
KerrT., MarshallB.D., MilloyM.J.Patterns of heroin and cocaine injection and plasma HIV-1 RNA suppression among a long-term cohort of injection drug users. Drug Alcohol Depend2012; 124: 108–112.
38.
SharpeT.T., LeeL.M., NakashimaA.K., Elam-EvansL.D., FlemingP.L.Crack cocaine use and adherence to antiretroviral treatment among HIV-infected black women. J Community Health2004; 29: 117–127.
39.
DutraL., StathopoulouG., BasdenS.L., LeyroT.M., PowersM.B., OttoM.W.A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry2008; 165: 179–187.
40.
GrabowskiJ., RhoadesH., StottsA.Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology2004; 29: 969–981.
41.
RushC.R., StoopsW.W.Agonist replacement therapy for cocaine dependence: a translational review. Future Med Chem2012; 4: 245–265.
42.
DakwarE., NunesE.V., BisagaA.A comparison of independent depression and substance-induced depression in cannabis-, cocaine-, and opioid-dependent treatment seekers. Am J Addict2011; 20: 441–446.
43.
LoobyA., EarleywineM.Negative consequences associated with dependence in daily cannabis users. Subst Abuse Treat Prev Policy2007; 2: 3.
44.
BovassoG.B.Cannabis abuse as a risk factor for depressive symptoms. Am J Psychiatry2001; 158: 2033–2037.
45.
CarrieriM.P., LeportC., ProtopopescuC.Factors associated with nonadherence to highly active antiretroviral therapy: a 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase. J Acquir Immune Defic Syndr2006; 41: 477–485.
46.
SullivanP.S., DworkinM.S.Prevalence and correlates of fatigue among persons with HIV infection. J Pain Symptom Manage2003; 25: 329–333.
47.
NieuwkerkP.T., OortF.J.Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: a meta-analysis. J Acquir Immune Defic Syndr2005; 38: 445–448.
48.
GolubE.T., LatkaM., HaganH.Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory. J Urban Health2004; 81: 278–290.
49.
FuhrerR., RouillonF., LellouchJ.Diagnostic reliability among French psychiatrists using DSM-III criteria. Acta Psychiatr Scand1986; 73: 12–16.
50.
ReichenbergA., GormanJ.M., DieterichD.T.Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. AIDS2005; 19Suppl 3: S174–S178.
51.
LagunoM., BlanchJ., MurillasJ.Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis C. Antivir Ther2004; 9: 905–909.
52.
MarcellinF., PreauM., RavauxI., DellamonicaP., SpireB., CarrieriM.P.Self-reported fatigue and depressive symptoms as main indicators of the quality of life (QOL) of patients living with HIV and hepatitis C: implications for clinical management and future research. HIV Clin Trials2007; 8: 320–327.
